State Street Corp Abeona Therapeutics Inc. Transaction History

State Street Corp

$2.8 Trillion
Q3 2025

A detailed history of State Street Corp transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 716,154 shares of ABEO stock, worth $3.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

716,154

Previous 585,880 22.24%

Holding current value

$3.19 Million

Previous $3.33 Million 13.65%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$5.28 - $7.23 $687,846 - $941,881	130,274 Added 22.24%	716,154 $3.78 Million
Q2 2025 Aug 14, 2025	BUY	$4.18 - $7.0 $1.63 Million - $2.73 Million	390,276 Added 199.52%	585,880 $3.33 Million
Q1 2025 May 15, 2025	BUY	$4.76 - $6.02 $57,120 - $72,240	12,000 Added 6.54%	195,604 $931,000
Q4 2024 Feb 14, 2025	BUY	$5.55 - $6.67 $134,914 - $162,141	24,309 Added 15.26%	183,604 $1.02 Million
Q3 2024 Nov 14, 2024	SELL	$4.12 - $6.32 $10,712 - $16,432	-2,600 Reduced 1.61%	159,295 $1.01 Million

Q2 2024 Aug 14, 2024	BUY	$3.17 - $8.05 $240,603 - $610,995	75,900 Added 88.26%	161,895 $686,000
Q1 2024 May 15, 2024	BUY	$4.07 - $8.68 $36,630 - $78,120	9,000 Added 11.69%	85,995 $623,000
Q4 2023 Feb 14, 2024	BUY	$3.71 - $5.14 $96,089 - $133,126	25,900 Added 50.69%	76,995 $385,000
Q2 2023 Aug 14, 2023	BUY	$2.76 - $5.27 $21,528 - $41,106	7,800 Added 18.02%	51,095 $205,000
Q1 2023 May 15, 2023	SELL	$2.25 - $3.27 $20,700 - $30,084	-9,200 Reduced 17.53%	43,295 $122,000
Q4 2022 Feb 14, 2023	BUY	$2.4 - $5.65 $89,760 - $211,310	37,400 Added 247.76%	52,495 $161,000
Q3 2022 Nov 15, 2022	BUY	$2.79 - $5.56 $42,115 - $83,928	15,095 New	15,095 $46,000

Others Institutions Holding ABEO

# of Institutions

109

Shares Held

32.9M

Call Options Held

1.34M

Put Options Held

271K

View Full List

About ABEONA THERAPEUTICS INC.

Ticker ABEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,950,380
Market Cap $26.5M
Description
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...

More about ABEO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Abeona Therapeutics Inc. Transaction History